Andere talen NervGen Pharma Corp.

Aandelen

NGEN

CA64082X2032

Beurs gesloten - Toronto S.E. Andere beurzen 21:59:59 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,33 ^CAD	+7,87%		+10,43%	-13,70%

17/04	NervGen rapporteert voor boekjaar 2023 een nettoverlies van $0,38 per aandeel en geeft een operationele update	MT
17/04	NervGen Pharma Corp. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

NervGen Engages Russo Partners LLC to Provide Public Relations Services	25/04
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	17/04
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates	17/04
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	09/04
NervGen Pharma Closes C$23 Million Bought Deal Financing	28/03
NervGen Completes $23 Million Bought Deal Financing	28/03
Canadian Investment Regulatory Organization Trade Resumption - NGEN	21/03
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units	21/03
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING	21/03
Canadian Investment Regulatory Organization Trading Halt - NGEN	21/03
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company	21/02
NervGen Pharma Grants Stock Options	20/02
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291	15/02
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	15/02
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates	09/11
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki	08/11
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23-10-23
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NervGen Pharma Corp.

Aandelen

NGEN

CA64082X2032

Andere talen

Filters